As expected, the pre-NAC tumor angiogenesis score was not associated with the rate of pathological complete response (pCR) in patients with either estrogen receptor (ER)-positive/human epidermal receptor 2 (HER2)-negative or triple negative breast cancer (TNBC) tumors (Figure 2B). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.